# TriVascular

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trivascular

- Industry: Medical Devices & Equipment
- Headquarters: Santa Rosa, US
- Website: www.trivascular.com
- Total disclosed funding: $255M
- Latest round: Series E (Nov 18, 2013)
- Investors on record: 10

## About

TriVascular, Inc. is a medical device company specializing in innovative endovascular solutions designed to treat abdominal aortic aneurysms (AAAs) through minimally invasive techniques.Founded in 1998 and headquartered in Santa Rosa, US, TriVascular develops advanced technologies for vascular interventions. The company underwent a significant transition with its latest round of funding in April 2014, culminating in a Merger that raised USD 211.00 mn led by Endologix. TriVascular has completed a total of 11 deals, with the latest deal dated April 16, 2014. The founder's history is not publicly specified.TriVascular primarily focuses on developing innovative endovascular solutions for the treatment of abdominal aortic aneurysms (AAAs). Their core product offerings include the Ovation Prime and Ovation Alto systems, which utilize advanced stent graft technology for a minimally invasive AAA repair approach. These products are designed to enhance procedural efficiency and improve patient outcomes. TriVascular serves hospitals, surgical centers, and vascular specialists across North America and Europe, addressing crucial medical needs in the vascular space.In 2014, TriVascular reported a revenue of USD 31.80 mn with an EBITDA of USD -48.77 mn, reflecting the company's financial performance during that year. Revenue generation is primarily through direct sales of its endovascular products to healthcare systems, often bundled with training and support services for medical personnel.In April 2014, TriVascular Technologies raised USD 78 mn in an IPO, selling 6.5 million shares at USD 12 per share at Nasdaq under the ticker TRIV. Future growth strategies include the development of new endovascular products aimed at expanding their market presence, as well as targeting additional geographical regions for expansion.

## Funding rounds

- Series E, Nov 18, 2013, $40M — Delphi Ventures, New Enterprise Associates, Glouston Capital Partners, Kearny Venture Partners, MPM BioImpact, Kaiser Permanente Ventures, Redmile Group, Deerfield Management, Rock Springs Capital
- Series D, Jun 4, 2012, $60M — Delphi Ventures, New Enterprise Associates, Pinnacle Ventures, Kearny Venture Partners, MPM BioImpact, Kaiser Permanente Ventures, Redmile Group
- Series C, Jul 12, 2010, $60M — Delphi Ventures, New Enterprise Associates, Pinnacle Ventures, Kearny Venture Partners, MPM BioImpact
- Series B, Nov 16, 2009, $30M — Delphi Ventures, New Enterprise Associates, Kearny Venture Partners, MPM BioImpact
- Series A, Mar 31, 2008, $65M — Delphi Ventures, New Enterprise Associates, Kearny Venture Partners, MPM BioImpact

## Investors

- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series A, Series B, Series C, Series D, Series E
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C, Series D, Series E
- Kearny Venture Partners (https://capitalatlas.ai/funds/kearny-venture-partners) — Series A, Series B, Series C, Series D, Series E
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C, Series D, Series E
- Pinnacle Ventures (https://capitalatlas.ai/funds/pinnacle-ventures) — Series C, Series D
- Kaiser Permanente Ventures (https://capitalatlas.ai/funds/kaiser-permanente-ventures) — Series D, Series E
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series D, Series E
- Glouston Capital Partners (https://capitalatlas.ai/funds/glouston-capital-partners) — Series E
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series E
- Rock Springs Capital — Series E